Quantcast

Latest BRAF Stories

2014-04-23 12:31:04

Three Phase 3 Trials Advancing in Patients with BRAF Melanoma, NRAS Melanoma and Low-Grade Serous Ovarian Cancer BOULDER, Colo., April 23, 2014 /PRNewswire/ -- Following the recent announcement by Novartis and GlaxoSmithKline that they have entered into a definitive agreement to exchange certain assets, Array BioPharma Inc. (NASDAQ: ARRY) reports that Novartis has indicated that it will continue to honor its obligations under the Array-Novartis agreement relating to binimetinib...

2014-04-09 08:28:30

QUÉBEC CITY, April 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, provides rationale for new therapeutic opportunities in oncology with this compound. The poster, titled, "Erk Inhibition as a Therapeutic Option for the Treatment of Raf- and Mek- Inhibitor Resistant Tumors", I. Seipelt, P. Schmidt, H. Märzhäuser, M. Gerlach, K. Jung, T....

2014-04-08 12:31:41

Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V600E mutation assay and tissue biopsy at baseline SAN DIEGO, April 8, 2014 /PRNewswire/ -- Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's (NASDAQ: TROV) molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients. The results were...

2014-04-01 08:28:44

SAN DIEGO, April 1, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California....

2014-03-26 12:26:20

The Highest Percentage of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next One to Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., March 26, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 45 percent of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF inhibitor Tafinlar for BRAF-mutation-positive unresectable or metastatic melanoma compared with 28...

2014-02-14 12:23:35

The Jeffrey Epstein VI Foundation backs the FDA's landmark decision to approve inhibitor cocktails for melanoma. NEW YORK, Feb. 14, 2014 /PRNewswire/ -- The well-known science philanthropist and founder of the Program for Evolutionary Dynamics at Harvard University, has heralded the Food and Drug Administration's approval of the first inhibitor combination clinical trial for melanoma patients. "It's about time," Jeffrey Epstein remarked who donated substantial funds to the...

2014-01-29 23:32:09

Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014 Today EntroGen (http://www.entrogen.com) announced immediate availability of its expanded colorectal cancer screening products. EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3 and 4 mutations in both genes. The Company has obtained a CE-IVD mark for these products. The importance of...

2014-01-28 16:25:04

DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMerieux's molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient. Clarient will use THxID® BRAF in order to aid oncologists in selecting metastatic melanoma patients whose tumors carry the BRAF V600E mutation for possible treatment with GlaxoSmithKline's (GSK) Tafinlar® (dabrafenib) as well as...

2014-01-16 14:22:49

University of Leicester researchers deploy 'precision medicine' to successfully target advanced form of leukaemia with skin cancer drug A team of scientists from the University of Leicester has demonstrated a novel treatment for Hairy Cell Leukaemia (HCL), a rare type of blood cancer, using a drug administered to combat skin cancer. The research, which is published today (Thursday 16 January) in the New England Journal of Medicine, indicates Vemurafenib, a BRAF inhibitor that has been...

2014-01-09 08:28:19

WASHINGTON, Jan. 9, 2014 /PRNewswire-USNewswire/ -- For years, researchers have believed that the most effective approach to treating melanoma is likely to be in combining two or more drugs together. Yesterday the FDA issued the first-ever approval of a drug combination for the treatment of this cancer. This combination involves a MEK inhibitor, trametinib, and a BRAF inhibitor, dabrafenib, both of which were approved by the FDA as single agents in May 2013. Inhibition of BRAF, an...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.